Toronto Raptors point guard Malachi Flynn discusses what it was like guarding Kyrie Irving and why he seems to make so many plays in the final 15 minutes or so of the game.
Toronto Raptors point guard Malachi Flynn discusses what it was like guarding Kyrie Irving and why he seems to make so many plays in the final 15 minutes or so of the game.
It varies depending on what state you live in.
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $165.3M in gross proceeds – BOSTON, May 13, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “The start of 2021 marked a pivotal time for Decibel as we successfully closed our upsized IPO. With this strong financial foundation, we are in a position to further advance our exciting pipeline of clinical, preclinical and discovery programs with the overarching goal of bringing the privileges of hearing and balance to people in need. In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency. We also established a critical cGMP manufacturing and development relationship with Catalent,” said Laurence Reid, Ph.D., Chief Executive Officer of Decibel. “Beyond DB-OTO, we remain encouraged by the progress in our gene therapy programs for congenital, monogenic hearing loss and look forward to announcing the program target for our AAV.104 program in 2021.” Company Highlights Closed Second Tranche of Series D Financing and Upsized Initial Public Offering: In February 2021, Decibel completed its Series D financing, closing the second tranche and receiving net proceeds of $27.4 million. Additionally, Decibel completed its Initial Public Offering (IPO) of 7,662,000 shares of common stock at a public offering price of $18.00 per share. Net proceeds from the offering, after deducting underwriting discounts and offering expenses, were approximately $124.8 million. Pipeline Progress Gene Therapies for Congenital, Monogenic Hearing Loss Continued Development of Lead Gene Therapy Program, DB-OTO, for Otoferlin (OTOF): In February 2021, Decibel established manufacturing capabilities for its lead gene therapy product candidate, DB-OTO. Under the new agreement, Catalent will provide Decibel with cGMP manufacturing and process and analytical development of DB-OTO.Presented New Preclinical Data on DB-OTO and Surgical Approach at the 44th Annual Association for Research in Otolaryngology Conference (ARO) and the Annual Scientific and Technology Conference of the American Auditory Society: In the first quarter of 2021, Decibel presented new preclinical findings to support the development of DB-OTO. Presentations highlighted data demonstrating that the Company’s proprietary dual vector technology and cell-selective promoter enabled expression of OTOF in hair cells and durably restored hearing in mice and drove highly selective expression of a reporter gene in hair cells of non-human primates across the cochlear length.On Track for DB-OTO Key Milestones in 2022: Decibel expects to submit an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) and/or a Clinical Trials Application (CTA) in Europe and initiate a Phase 1/2 clinical trial for DB-OTO in pediatric patients with congenital hearing loss in 2022.Preclinical Pipeline Expansion Continues: Decibel expects to announce the program target for its AAV.104 discovery program in patients with autosomal recessive hearing disorders in 2021. Gene Therapies for Hair Cell Regeneration Preclinical Pipeline Expansion Continues: Decibel continues to advance DB-ATO and AAV.201, its gene therapy programs for regeneration of hair cells in the vestibule for the treatment of bilateral vestibulopathy, and its gene therapy program to regenerate hair cells in the cochlea for the treatment of sensorineural hearing loss. Based on findings from recently completed behavioral studies of DB-ATO, the Company did not see sufficient functional recovery to continue to move DB-ATO to development candidate in 2021. The Company plans to announce the program target for AAV.201 in 2022. Otoprotection Therapeutic Updated Timeline to Report Interim Results from Phase 1b Proof-of-Concept Trial of DB-020 for the Treatment of Cisplatin-Induced Hearing Loss: The reporting of interim results from the ongoing Phase 1b clinical trial of DB-020 in patients with cisplatin-induced hearing loss is now expected in the first half of 2022 due to continued impact of the COVID-19 pandemic on the pace of patient recruitment in the United States. Due to COVID-19 restrictions, sites in the United States have been delayed in recruiting, but are now open and actively recruiting for the trial, along with the active sites in Australia. First Quarter 2021 Financial Results: Cash Position: As of March 31, 2021, cash, cash equivalents and available-for-sale securities were $191.1 million, compared to $54.3 million as of December 31, 2020. The increase in cash, cash equivalents and available-for-sale securities was due to the sale of the Company’s Series D convertible preferred stock and common stock in the Company’s IPO completed in February 2021.Research and Development Expenses: Research and development expenses were $6.0 million for the first quarter of 2021, compared to $7.4 million for the first quarter of 2020. The decrease in research and development expenses for the first quarter of 2021 was primarily due to $1.8 million decrease in personnel-related costs due to reduced headcount, driven primarily by a reduction-in-force conducted in January 2020 and a $0.8 million decrease in expenses incurred for our DB-020 program driven by decreased activity as a result of delays due to the COVID-19 pandemic, partially offset by an increase of $1.2 million in other indirect research and development expenses.General and Administrative Expenses: General and administrative expenses were $4.9 million for the first quarter of 2021, compared to $4.2 million for the same period in 2020. The increase in general and administrative expenses for the first quarter of 2021 was primarily attributable to $1.0 million increase in professional fees, driven primarily by expenses related to consulting, accounting advisory and audit services incurred as a result of becoming a public company in February 2021. Financial Guidance: Based on its current operating and development plans, Decibel believes that its existing cash, cash equivalents and available-for-sale securities will fund its pipeline programs and operating expenses into 2024. About Decibel Therapeutics Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Decibel’s strategy, future operations, prospects, plans, objectives of management, the therapeutic potential for Decibel’s product candidates and preclinical programs, the potential benefits of cell-selective expression, the expected timeline for submitting investigational new drug applications and achieving other planned milestones, expectations regarding the translation of preclinical findings to human disease and the sufficiency of Decibel’s existing cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Decibel may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials, the timing of and Decibel’s ability to submit and obtain approval to initiate clinical development of its program candidates, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, whether Decibel’s cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, uncertainties related to the impact of the COVID-19 pandemic on Decibel’s business and operations, as well as the risks and uncertainties identified in Decibel’s filings with the Securities and Exchange Commission (SEC), including those risks detailed under the caption “Risk Factors” in Decibel’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021. In addition, the forward-looking statements included in this press release represent Decibel’s views as of the date of this press release. Decibel anticipates that subsequent events and developments will cause its views to change. However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Decibel’s views as of any date subsequent to the date of this press release. Condensed Consolidated Balance Sheets(unaudited) (in thousands) March 31, 2021 December 31, 2020Cash, cash equivalents and available-for-sale securities$191,077 $54,310 Total assets 207,086 67,285 Convertible preferred stock - 93,091 Total stockholders' deficit (173,559) (162,689) Condensed Consolidated Statement of Operations(unaudited) (in thousands) For the three months ended March 31, 2021 March 31, 2020Operating expenses: Research and development $6,020 $7,436 General and administrative 4,883 4,178 Total Operating expenses 10,903 11,614 Loss from operations (10,903) (11,614)Other income: Interest income 33 79 Total other income, net 33 79 Net loss $(10,870) $(11,535) Investor Contact:Julie SeidelStern IR, Inc.firstname.lastname@example.org Media Contact:Chris Railey Ten Bridge Communicationschris@tenbridgecommunications.com
TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Mercer Park Brand Acquisition Corp. (NEO: BRND.A.U; OTCQX: MRCQF; “BRND” or the “Company”), a Special Purpose Acquisition Company (SPAC) which has entered into a definitive agreement to merge (the “Glass House Group Transaction”) with GH Group, Inc. (“GH Group”), California’s leading fully-integrated cannabis business, is updating the status of its proposed merger with GH Group. To facilitate the closing of the Glass House Group Transaction, the holders of the Company’s class A restricted voting shares have approved an extension of the Company’s permitted timeline to complete a qualifying transaction to July 30, 2021 (the “Extension”). The Company’s board of directors has also approved the Extension, which is effective as of May 13, 2021. After processing notices of redemption received with respect to the Extension, BRND expects that immediately prior to the closing of the Glass House Group Transaction it will have an aggregate of approximately US$266 million (assuming no additional redemptions and including the previously announced private placement expected to close concurrently with the Glass House Transaction) to fund its growth strategy and pay transaction expenses. 22,406,149 class A restricted voting shares were redeemed in connection with the Extension. As previously announced, the Company and GH Group announced a business combination to create the largest cannabis brand-building platform in California, the world’s largest cannabis market. GH Group will support its existing and future portfolio of brands with unmatched capacity and distribution in the state. The combined company has planned expansions to reach 6 million ft2 of cultivation in state-of-the-art greenhouses, representing by far the largest capacity of any cannabis operator in California and an anticipated retail footprint of 21 operational dispensaries by Q1 2022, more than double the next largest retail operator in the state. “We view successful cannabis brand-building as a combination of four factors: the ability to control quality biomass at a large scale; produce at the most competitive costs; offer the highest quality products; and deliver the best value proposition to consumers. Glass House has a track record of excellence across all four of these drivers. Combined with the proposed combination with the Southern California Greenhouse asset and 17 proposed Element 7 retail licenses, Glass House Group is poised to become the largest, vertically integrated brand-building platform in California, the world’s largest cannabis market,” said BRND Chairman Jonathan Sandelman. Commenting on the transaction, Glass House’s co-founder and CEO, Kyle Kazan, stated: “We have established a strong retail and wholesale network and best-in-class cultivation processes, all anchored by a scaled and highly efficient cost structure. I am incredibly proud of the robust operation we have built over the past five years, and we look forward to augmenting these strengths to further capitalize on the growing statewide and national CPG opportunity.” About Mercer Park Brand Acquisition Corp. BRND is a special purpose acquisition corporation launched in May 2019 to create the leading branded cannabis company in the U.S. For more information about BRND, please visit the BRND website at www.mercerparkbrand.com. About GH Group, Inc. GH Group is a rapidly growing, vertically integrated, California-focused organization that strives every day to realize its vision of excellence: compelling cannabis brands, produced sustainably, for the benefit of all. Led by a team of expert operators, proven businesspeople, and passionate plant lovers, it is dedicated to delivering rich cannabis experiences with respect for people, for the environment, and for the community, and an abiding commitment to justice, social equity, and sustainability. Risk Factors This investment opportunity involves a high degree of risk. You should carefully consider the risks and uncertainties described under “Risk Factors” in the Prospectus. If any of the risks and uncertainties described thereunder actually occur, alone or together with additional risks and uncertainties not currently known to BRND or GH Group, or that they currently do not deem material, BRND’s and GH Group’s business, financial condition, results of operations and prospects may be materially adversely affected. There can be no assurance that the Glass House Group Transaction will be completed, or, if it is, that the resulting company will be successful. Additional Information About the Proposed Business Combination and Where to Find It BRND and GH Group urge investors, shareholders and other interested persons to read the documents (including the Prospectus and Circular) filed with Canadian securities regulatory authorities in connection with the Glass House Group Transaction, as these materials contain important information about BRND, GH Group, the resulting company and the Glass House Group Transaction. Company Contact: Megan KulickT: (646) 977-7914Email: IR_BRND@mercerparklp.com Investor Relations Contact: Cody Cree or Jackie KeshnerGateway Investor RelationsT: (949) 574-3860Email: BRND@GatewayIR.com
Henry Schein announces $400 million increase to share repurchase plan.
BRP Inc. (TSX: DOO) (NASDAQ: DOOO) will hold its first quarter FY2022 financial results conference call on Thursday, June 3, 2021, followed by its Annual Meeting of Shareholders.
Roblox Corporation (NYSE: RBLX) shares plunged in Thursday trading to close the day down 7.8%. This was the second day in a row of prices falling since the company reported blockbuster sales growth in its first earnings report post-IPO. As videogameschronicle.com reported late Tuesday (perhaps not coincidentally, just hours after the earnings report that sent Roblox stock flying), video game producer Ubisoft is shifting its business model away from relying solely on sales of high-price "AAA releases" and evolving to offer a "high-quality line-up that is increasingly diverse," including "building high-end free-to-play games."
Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that, due to market conditions, pricing for its previously-announced equity offering (the "Offering") will be temporarily delayed.
U.S. shares rebounded on Thursday after falling for three consecutive days and benchmark Treasury yields dipped, as investors snapped up stocks that would benefit from an economic recovery and shrugged off worries about rising prices, for now. After posting their biggest slump in at least 11 weeks on Wednesday, U.S. shares bounced back as investors flush with cash looked past concerns that accelerating inflation may prompt interest rate hikes sooner, and deployed their funds once more. So intent were investors on leaving inflation worries aside that financial markets barely responded to Thursday's data, which showed U.S. producer prices posting their biggest annual gain since 2010 in April.
A federal judge refused Thursday to free a Texas man whom authorities have accused of planning an attack on a social media company's facility after he returned home from storming the U.S. Capitol. Guy Wesley Reffitt, one of more than 400 federal defendants charged in the Jan. 6 riot at the Capitol, has been identified by prosecutors as a member of a militia-style group linked to the anti-government Three Percenters extremist movement. Reffitt bragged about his actions in Washington, D.C., on Jan. 6 during a Zoom meeting with two other militia members four days after the siege, according to prosecutors.
Even with COVID-19 on the wane, we're still feeling aftereffects. One is getting gas to the stations. Find out more.
Ronnie Ortiz-Magro's attorneys said that the Jersey Shore star "is currently seeking medical treatment for psychological issues that he has ignored for a long time"
TORONTO — North American stock markets rebounded from a three-day slide in a relief rally after an erratic start to the week on mounting concerns about inflation. "It looks like the cyclical bull market is going to extend here for a while longer," said Candice Bangsund, portfolio manager for Fiera Capital. Markets were rattled earlier in the week by reports of consumer and producer inflation beating expectations. "But inevitably it would appear that these are indeed fleeting and will not alter the accommodating monetary policy stance from global central banks," Bangsund said in an interview. A pullback in the energy sector caused the S&P/TSX composite index to lag its U.S. counterparts, closing up just 28.04 points to 19,135.81. In New York, the Dow Jones industrial average was up 433.79 points at 34,021.45. The S&P 500 index was up 49.46 points at 4,112.50 while the Nasdaq composite was up 93.31 points at 13,124.99. The rally was accompanied by a rotation from growth sectors like technology to so-called cyclical and value-oriented sectors that thrive amid an economic recovery. Seven of the 11 major sectors on the TSX were higher, including consumer discretionary, financials and industrials. Discretionary led as blowout earnings from Canadian Tire Corp. Ltd. pushed its shares up 10.6 per cent. Despite a dip in bond yields, the heavyweight financials sector was up 1.3 per cent as Canada's big banks saw their shares rise by as much as 2.5 per cent on the day. Bangsund said investors might be taking advantage of the recent pullback in cyclically oriented sectors to buy shares as part of the reflationary rotation narrative playing out. Industrials climbed with shares of WSP Global Inc. increasing 9.2 per cent after reporting strong quarterly results. The main outlier was energy, which fell two per cent as crude oil prices dropped 3.4 per cent. The June crude contract was down US$2.26 at US$63.82 per barrel and the June natural gas contract was up less than a penny at US$2.97 per mmBTU. Crescent Point Energy Corp. was down 6.5 per cent, Vermilion Energy Inc. decreased 6.4 per cent and MEG Energy Corp. was 5.9 per cent lower. Crude prices fell after the Colonial Pipeline was set to return to service, alleviating some of the restraint on supply. Investors appear unfazed by ongoing high COVID-19 infections in India and South America that would reduce demand, Bangsund said, as they mainly focus on positive signals in developed economies, including lower case numbers, ramped up vaccinations and progress in the economic reopening in the U.S. and Britain. The U.S. reported that jobless claims fell last week to 473,000, a new pandemic low. The U.S. Centers for Disease Control and Prevention said on Thursday that fully vaccinated people no longer need to wear a face mask or remain two metres away from others in most settings. "Europe, Canada is likely to follow, so in the developed economies the end of the pandemic is in sight, though of course in the emerging world it's a different story." The Canadian dollar traded for 82.30 cents US compared with 82.67 cents US on Wednesday. Although Nasdaq bounced back, Canada's tech sector continued to fall as Shopify Inc. and Lightspeed POS Inc. lost 3.4 and 3.1 per cent, respectively. Materials also dipped on a decrease in copper prices, pushing Turquoise Hill Resources Ltd. off 18.5 per cent and Pan American Silver Corp. down 10.3 per cent. The June gold contract was up US$1.20 at US$1,824.00 an ounce and the July copper contract was down 4.55 cents at US$4.69 a pound. "With both consumer and producer prices accelerating, this is added to signs of near-term pricing pressures and boosted gold prices due to its role as an inflationary hedge in the portfolio setting," Bangsund said. This report by The Canadian Press was first published May 13, 2021. Companies in this story: (TSX:PAAS, TSX:TRQ, TSX:SHOP, TSX:LSPD, TSX:WSP, TSX:BMO, TSX:MEG, TSX:CPG, TSX:VET, TSX.CTC.A, TSX:GSPTSE, TSX:CADUSD=X) Ross Marowits, The Canadian Press
Harvey Mason, jr. has been named the official president/CEO of the Recording Academy by the organization’s board of trustees, it announced on Thursday. Mason has been serving as the unpaid interim president/CEO since January of last year. He will relinquish his role as chair of the board of trustees, which he had held since 2019. […]
Bridal party style just got that much cooler.
Aeva Technologies Inc on Thursday said it signed a deal to develop a sensor for a self-driving car to be made by an "undisclosed large company," and its shares rose even as it reported that its loss ballooned and sales came in far below forecasts. Aeva reported first-quarter revenue of $300,000, down from $500,000 a year earlier and far below analyst estimates of $1.38 million, according to Refinitiv estimates. Founded by two ex-Apple Inc, Aeva makes a sensor that helps self-driving cars navigate through the use of lidar, a technology that uses lasers much like radar uses radio waves.
NHS England said all surgeries must offer in-person reception services and appointments following concerns over remote access during the pandemic.
Yahoo Finance's Jared Blikre joined Yahoo Finance Live to break down DoorDash's latest earnings report.
Jeff Blackburn, a former high-level Amazon exec who just recently left after more than two decades, is coming back — in a newly created role, giving him oversight over a consolidated media group. The new appointment was announced internally Thursday by Andy Jassy, currently CEO of Amazon Web Services (AWS), who is set to succeed […]
Improving jobless benefits data show Florida’s economic recovery appears back in full swing.
Borussia Dortmund's Jadon Sancho and Erling Haaland scored two goals apiece to crush RB Leipzig 4-1 and lift the German Cup on Thursday. England international Sancho curled a superb shot into the top corner in the fifth minute and added another with a quick break on the stroke of halftime after Haaland, back from injury, powered into the box and flicked the ball past keeper Peter Gulacsi. Dortmund were brutally efficient in the first half, scoring with each of their three shots on target.